Adverum Biotechnologies Inc's Business Segments

Adverum Biotechnologies Inc is a clinical-stage biotechnology company that focuses on developing gene therapies to treat diseases using its proprietary technology platform. The company was founded in 2006 and is headquartered in Redwood City, California.

Adverum's main objective is to provide novel treatments for patients with serious medical conditions by harnessing the power of gene therapy. Gene therapy involves introducing genetic material into a patient's cells to correct a genetic defect or provide therapeutic benefits. This innovative approach aims to address the root cause of diseases rather than merely treating the symptoms.

The company's technology platform is centered around the use of adeno-associated viruses (AAVs) as delivery vehicles for transporting therapeutic genes into specific cells in the body. AAVs are a class of small viruses that are not known to cause disease in humans and have shown promising safety profiles in clinical trials. Adverum has developed its own proprietary AAV vectors, which are designed to efficiently deliver genes to the targeted cells with high levels of durability and efficacy.

Adverum has a diversified pipeline of gene therapies that target various diseases, including ocular conditions and rare genetic disorders. Their lead candidate, ADVM-022, is being investigated as a potential one-time intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a chronic eye disease that can lead to severe vision loss, and current treatments often require frequent injections. ADVM-022 is designed to provide sustained expression of an anti-VEGF protein, which can reduce the need for frequent injections.

In addition to wet AMD, Adverum is also developing gene therapies for other ocular diseases such as diabetic retinopathy and hereditary angioedema. They are also exploring the potential of their technology in treating rare genetic diseases like alpha-1 antitrypsin deficiency and hereditary retinal disorders.

The company's research and development capabilities are supported by a dedicated team of scientists, researchers, and industry experts. They have established collaborations with academic institutions, healthcare organizations, and biopharmaceutical companies to advance their pipeline and expand their gene therapy platform.

Adverum's goal is to bring safe and effective gene therapies to patients in need, improving their quality of life and potentially offering long-lasting solutions for diseases that currently have limited treatment options. They are committed to conducting rigorous clinical trials, ensuring regulatory compliance, and working towards commercialization of their gene therapies.

Adverum Biotechnologies Inc. is a publicly-traded biotechnology company primarily engaged in the development of gene therapies targeting serious ocular diseases and rare genetic disorders. With a mission to improve patients quality of life, Adverums diverse range of products and services reflects its commitment to addressing unmet medical needs in these critical areas.

1. Gene Therapy Segment:
The cornerstone of Adverum Biotechnologies operations is its focus on gene therapy, a revolutionary treatment modality that involves delivering genetic material into patients cells with the aim of treating diseases caused by genetic abnormalities. This segment encapsulates the companys core research and development initiatives, positioning it at the forefront of biotechnology.

Ocular Diseases:
Adverum Biotechnologies concentrates on the development of gene therapies for a range of ocular diseases, which include both inherited and acquired conditions. The companys innovative therapies target several critical ophthalmic disorders, including:

- Wet Age-Related Macular Degeneration (AMD):
- ADVM-022: This gene therapy candidate is specifically designed to treat wet AMD, which is a leading cause of severe vision loss among the elderly population. ADVM-022 aims to introduce a gene that encodes an anti-VEGF (vascular endothelial growth factor) protein into the retina, which is intended to inhibit the abnormal blood vessel growth and fluid leakage that characterizes this condition.

- Diabetic Macular Edema (DME):
- ADVM-032: Targeting DME, a common complication of diabetic retinopathy that can lead to vision impairment, ADVM-032 is engineered to deliver a similar anti-VEGF gene as seen in ADVM-022. By reducing pathological microvascular leakage and abnormal blood vessel formation, this therapy seeks to improve the overall health of the retina in diabetic patients.

- Hereditary Retinal Diseases:
- Adverum is also developing therapies for a variety of hereditary retinal diseases, such as Best disease and Lebers congenital amaurosis. These programs are designed to rectify genetic mutations by supplying functional genes directly to the affected retinal cells, with the ultimate goal of restoring or improving vision in patients with these debilitating conditions.

Rare Diseases:
Beyond ocular conditions, Adverum Biotechnologies has expanded its focus to include gene therapies aimed at treating rare diseases stemming from genetic defects. The companys expertise allows it to tackle specific genetic mutations, potentially bringing hope to patients with few or no treatment options available. Notable efforts include:

- Alpha-1 Antitrypsin Deficiency (Alpha-1):
- ADVM-043: This gene therapy candidate targets Alpha-1, a genetic disorder that can result in serious lung and liver complications due to a deficiency in the alpha-1 antitrypsin protein. The therapy seeks to deliver a functional copy of the SERPINA1 gene, which encodes for this protein, thereby improving the levels of alpha-1 antitrypsin in patients and addressing the root cause of the disease.

Preclinical Pipeline and Technology:
In addition to its lead candidates aimed at ocular and rare diseases, Adverum boasts a strong preclinical pipeline that explores further gene therapy possibilities targeting additional ocular conditions and rare genetic disorders. The company leverages its proprietary technology platform, VectorGraft, which utilizes customized viral vectors to safely and efficiently deliver therapeutic genes. This platform holds significant potential for expanding Adverums gene therapy initiatives into a broader range of indications, enhancing treatment strategies across varying disease states.

Conclusion:
Adverum Biotechnologies Inc. presents a comprehensive portfolio of gene therapy products and services that focus primarily on ocular diseases like wet AMD and DME, along with impactful therapies targeting rare diseases such as Alpha-1 antitrypsin deficiency and genetic retinal disorders. Through its robust research and development pipeline and innovative technological capabilities, the company aims to provide transformative solutions that significantly enhance patient care and outcomes in these areas of urgent medical need.